» Articles » PMID: 15149548

Role of Promoter Hypermethylation in Cisplatin Treatment Response of Male Germ Cell Tumors

Abstract

Background: Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. The genetic pathway(s) that determine the chemotherapy sensitivity in GCT remain largely unknown.

Results: We studied epigenetic changes in relation to cisplatin response by examining promoter hypermethylation in a cohort of resistant and sensitive GCTs. Here, we show that promoter hypermethylation of RASSF1A and HIC1 genes is associated with resistance. The promoter hypermethylation and/or the down-regulated expression of MGMT is seen in the majority of tumors. We hypothesize that these epigenetic alterations affecting MGMT play a major role in the exquisite sensitivity to cisplatin, characteristic of GCTs. We also demonstrate that cisplatin treatment induce de novo promoter hypermethylation in vivo. In addition, we show that the acquired cisplatin resistance in vitro alters the expression of specific genes and the highly resistant cells fail to reactivate gene expression after treatment to demethylating and histone deacetylase inhibiting agents.

Conclusions: Our findings suggest that promoter hypermethylation of RASSF1A and HIC1 genes play a role in resistance of GCT, while the transcriptional inactivation of MGMT by epigenetic alterations confer exquisite sensitivity to cisplatin. These results also implicate defects in epigenetic pathways that regulate gene transcription in cisplatin resistant GCT.

Citing Articles

Research progress on the fanconi anemia signaling pathway in non-obstructive azoospermia.

Xu H, Zhang Y, Wang C, Fu Z, Lv J, Yang Y Front Endocrinol (Lausanne). 2024; 15:1393111.

PMID: 38846492 PMC: 11153779. DOI: 10.3389/fendo.2024.1393111.


Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship.

Nicu A, Ionel I, Stoica I, Burlibasa L, Jinga V Biomedicines. 2024; 12(5).

PMID: 38791003 PMC: 11117643. DOI: 10.3390/biomedicines12051041.


Pharmacological agents targeting drug-tolerant persister cells in cancer.

Chen Y, Gowda K, Amin S, Schell T, Sharma A, Robertson G Pharmacol Res. 2024; 203():107163.

PMID: 38569982 PMC: 11734664. DOI: 10.1016/j.phrs.2024.107163.


Role of Epigenetics for the Efficacy of Cisplatin.

Lumpp T, Stosser S, Fischer F, Hartwig A, Koberle B Int J Mol Sci. 2024; 25(2).

PMID: 38256203 PMC: 10816946. DOI: 10.3390/ijms25021130.


Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.

Wu Y, Lin Z, Tang X, Tong Z, Ji Y, Xu Y Front Immunol. 2023; 14:1182030.

PMID: 37388742 PMC: 10300279. DOI: 10.3389/fimmu.2023.1182030.


References
1.
Pfeifer G, Yoon J, Liu L, Tommasi S, Wilczynski S, Dammann R . Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002; 383(6):907-14. DOI: 10.1515/BC.2002.097. View

2.
Zamble D, Mikata Y, Eng C, Sandman K, Lippard S . Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J Inorg Biochem. 2002; 91(3):451-62. DOI: 10.1016/s0162-0134(02)00472-5. View

3.
Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher E, Latif F . Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene. 2003; 22(3):461-6. DOI: 10.1038/sj.onc.1206119. View

4.
Chen W, Zeng X, Carter M, Morrell C, Yen R, Esteller M . Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003; 33(2):197-202. DOI: 10.1038/ng1077. View

5.
Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003; 4(2):75-85. DOI: 10.1016/s1470-2045(03)00979-3. View